Small-molecule signal-transduction inhibitors: targeted therapeutic agents for single-gene disorders

Area of Science:

• Genetics
• Pharmacology
• Molecular Biology

Background:

• Over 2000 human genes are linked to inherited diseases, many rare and poorly understood.
• Genes encoding intracellular signaling pathways are frequently implicated, regulating cell growth, differentiation, and survival.
• Mutations in these genes can lead to disorders from birth defects to cancer.

Purpose of the Study:

• To review the therapeutic use of small-molecule drugs targeting intracellular signaling networks in single-gene disorders.
• To discuss the limitations and clinical development challenges of these targeted therapies for rare genetic diseases.

Main Methods:

• Literature review of recent examples of small-molecule drugs targeting signaling pathways in genetic disorders.
• Analysis of the therapeutic potential and clinical development hurdles for these approaches.

Main Results:

• Small-molecule drugs can effectively target components of signaling networks in Mendelian disorders.
• The causal link between mutations and disease provides opportunities for targeted therapeutic intervention.
• Numerous examples demonstrate the application of this strategy in rare genetic conditions.

Conclusions:

• Targeting intracellular signaling pathways is a promising therapeutic strategy for rare genetic diseases.
• Clinical development of these molecularly targeted therapies faces significant limitations and challenges.
• Further research is needed to overcome hurdles in bringing these treatments to patients with rare genetic disorders.